Acquired Company
Forbion European Acquisition Corp completed its business combination with enGene Inc., resulting in enGene Holdings Inc. becoming a publicly traded company with ENGN trading on Nasdaq beginning November 1, 2023.
enGene Holdings Inc. is a clinical-stage biotechnology company based in Saint-Laurent, Canada, dedicated to developing innovative genetic medicines targeting mucosal tissues and various organs. Leveraging state-of-the-art delivery technologies, the company aims to enhance the safety and efficacy of its proprietary therapeutic platform, addressing significant unmet medical needs in genetic therapies. With a diverse pipeline actively progressing through clinical trials, enGene is well-positioned to make transformative contributions to the field of genetic medicine and improve patient outcomes across various therapeutic indications. Show more
Location: 4868 RUE LEVY, MONTREAL, QC, CANADA, H4R 2P1, Montreal, QC, H4R 2P1, USA | Website: https://www.engene.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
638.4M
52 Wk Range
$2.65 - $12.25
Previous Close
$10.27
Open
$10.94
Volume
302,542
Day Range
$9.51 - $11.38
Enterprise Value
476.4M
Cash
50.15M
Avg Qtr Burn
-24.96M
Insider Ownership
0.09%
Institutional Own.
84.25%
Qtr Updated
10/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Detalimogene (EG-70) Details Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 Data readout |